Abstract
Patient financing can create meaningful value when it improves affordability, expands access, generates incremental provider revenue, or accelerates cash at an economically justified cost. The Patient Financing Fit Test provides an Economic Intelligence standard for determining whether financing fulfills those value propositions and produces a stronger patient-provider outcome than the available alternatives.
Introduction
Patient financing begins with the right intent: more time for patients to pay, less repayment friction, stronger revenue performance, accelerated cash, and reduced collection risk.
As adoption expanded, however, financing’s value became increasingly inferred from enrollment, adherence, default rates, financed volume, and cash advanced. Those measures describe program activity, but they are often treated as evidence that financing improved affordability, enabled access, generated incremental revenue, or delivered economically justified cash acceleration—without the comparative analysis needed to establish those outcomes.
This essay addresses that evidentiary gap through an objective Patient Financing Fit Test.
Credit Suitability Is Not Healthcare Financing Fit
Traditional credit analysis determines whether a consumer can support a credit product and on what terms. Measures such as FICO, VantageScore, repayment history, and delinquency signals estimate repayment probability, default exposure, and expected loss. They remain relevant whenever healthcare financing extends credit.
Traditional credit measures establish credit suitability: whether the patient’s capacity and risk profile support the proposed product and terms. They do not establish healthcare financing fit. Patient adoption may reflect convenience or self-selection rather than economic need or value.
Unlike conventional consumer credit, where financing may determine whether a purchase can occur, healthcare financing is often introduced after care has already been delivered.
The relevant test is therefore whether financing improves affordability, enables access, creates incremental provider revenue, or produces greater patient-provider value than the available alternatives.
The Patient Financing Fit Test
The Patient Financing Fit Test determines whether financing produces a stronger patient-provider outcome across these four dimensions—not simply whether it is offered, selected, funded, or repaid.
Affordability
Affordability requires three determinations: Is the balance correct? Is the payment structure sustainable? Is financing genuinely necessary?
The first test is whether the balance itself is correct. Affordability cannot be assessed until the patient’s actual obligation is known. Although balances entering financing are generally assumed to be accurate, missed coverage can materially change what a patient owes. Experian Health reported identifying previously unknown billable insurance in more than 27.5% of self-pay accounts screened through its Coverage Discovery solution.[1]
Coverage is only one source of potential overstatement. Patients may enter financing before charity care, financial assistance, hardship, prompt-pay, or other adjustments have been fully evaluated and applied. Some may qualify for assistance but never complete an application, while others may repay quickly enough to have qualified for a prompt-pay discount not reflected in the financed amount. In each case, the financed balance may exceed the patient’s true responsibility. Across every economic class, a lower legitimate obligation is inherently more affordable.
The second test is payment sustainability. Even when the balance is correct, can the patient reasonably sustain the proposed obligation and term? Balance size, repayment period, patient capacity, and likely downstream consequences must be considered together. A lower monthly payment may reduce immediate pressure, but it is not truly affordable if it merely extends an unsustainable obligation or increases the likelihood of future default and financial hardship.
The third test is financing necessity. Does the patient require financing, or simply prefer to spread payments over time? Federal Reserve research in the adjacent buy-now-pay-later market reinforces the distinction: 88% of users cited payment timing or convenience, compared with 57% who cited necessity. Although the markets differ, utilization alone does not establish an affordability-based need.[2]
Access
Did financing remove a meaningful barrier to receiving care?
Financing can create access when a patient could not otherwise proceed with elective, deferrable, or continuing treatment because of an immediate payment obligation. In those cases, the relevant evidence is not simply that the patient enrolled, but that financing materially changed the care decision—allowing treatment to begin, continue, or occur sooner than it otherwise would have.
The distinction is especially important in hospital settings. Much of hospital care is emergent, medically necessary, scheduled, or already completed and is not typically conditioned on financing enrollment. Financing offered after care has been delivered may improve the patient’s payment experience, but it did not create access to that episode of care.
Financing may still protect future access by preventing an existing balance from discouraging follow-up treatment, medication adherence, or continued engagement with the health system. That value, however, should be demonstrated through evidence of reduced delay, avoidance, or abandonment—not inferred from enrollment, satisfaction, or Net Promoter Score alone.
The access test is therefore direct: Did financing enable, accelerate, or preserve care that the patient would otherwise have delayed, declined, or discontinued?
Incremental Provider Revenue
Did financing create revenue the provider was unlikely to receive through another pathway?
A financed account that pays is a positive result. It becomes incremental revenue only when the payment exceeds what the provider was reasonably expected to receive through the next-best available pathway.
That determination requires more than comparing the full patient population with a smaller, selectively enrolled financing cohort. The groups may differ in balance size, repayment capacity, engagement, account age, credit profile, and preexisting likelihood of payment.
Without controlling for those differences, stronger performance among financed accounts may reflect patient selection rather than program impact. Financing creates incremental revenue only when economically comparable accounts outperform what they would have generated through direct payment, an internal payment plan, assistance, continued engagement, or another lower-cost pathway.
A credible comparison requires economically similar populations, consistent balance-aging periods, and equivalent operating conditions.
Cash Acceleration
Was cash needed earlier, and did its value exceed its economic cost?
Cash acceleration has value only when two conditions are met. First, financing must preserve or improve expected revenue. If the financed amount is lower than what the provider would likely have collected through the next-best pathway, financing may simply accelerate a weaker economic result.
Second, the provider must benefit materially from receiving cash earlier. This proposition is most compelling for organizations facing genuine liquidity or working-capital constraints, not necessarily for systems holding substantial reserves. Fitch reported median liquidity of 215.1 days cash on hand among rated nonprofit hospitals and health systems in fiscal 2024.[3] A 2025 L.E.K. survey found a divided market: approximately half of health systems described their financial position as constrained and half as solid or strong, while more than half reported fewer than 180 days cash on hand.[4]
The value of acceleration should therefore be measured against actual liquidity need, program fees, discounts, recourse exposure, transferred risk, and revenue otherwise collectible at comparable velocity or lower cost.
Snapshot: What Happens When Financing Fit Is Applied
An anonymized regional health-system example involving a leading revenue-cycle platform and patient-financing firm illustrates the difference between broad financing access and economically directed financing.[5]
Under the original model, financing outreach began at approximately day 30, with the provider receiving a non-recourse advance of roughly $0.70 on the dollar—an effective economic cost of approximately 30% for cash acceleration and risk transfer.
Financing-fit logic replaced open enrollment by directing accounts first through lower-cost pathways based on incremental-revenue potential and demonstrated financing need.
Following the change:
- payment-plan volume declined by approximately 57%;
- financed-provider payments declined by approximately 42%;
- the average financed balance increased by approximately 43%; and
- the average financing term increased by approximately 23%.
The changed cohort suggests that financing became concentrated among accounts with greater demonstrated need, while accounts more likely to resolve through lower-cost pathways were directed elsewhere.
Overall patient-payment performance remained broadly comparable, while the effective cost structure for redirected accounts moved from approximately 30% toward roughly 3%—a nearly 90% reduction in financing-related expense.
The result was not less patient-provider value, but more efficient pathway selection. Financing was preserved where its flexibility, risk-transfer, or acceleration benefits were economically justified and avoided where a lower-cost alternative could produce an equal or stronger outcome.
Market-Forward: Financing as an Accountable Pathway
The Patient Financing Fit Test moves the market from broad product availability to economically accountable pathway selection. The advancement is not less financing, but better-fit financing—used where it meaningfully improves affordability, enables access, creates incremental revenue, or accelerates cash at an economically justified cost.
References
- Experian Health. “5 Patient-Friendly Billing Practices to Speed Up Collections.” March 9, 2023. Experian reported that Coverage Discovery identified previously unknown billable insurance in more than 27.5% of self-pay accounts screened in 2021. This represents vendor-reported solution performance rather than a universal market prevalence rate.
- Wang, J., and W. Ouyang. “‘The Only Way I Could Afford It’: Who Uses Buy Now, Pay Later and Why.” Board of Governors of the Federal Reserve System, FEDS Notes, December 20, 2024. Findings are based on the 2022 and 2023 Survey of Household Economics and Decisionmaking. The adjacent BNPL market is used directionally and is not presented as equivalent to patient financing.
- Fitch Ratings. U.S. Not-for-Profit Hospitals and Health Systems Median Ratios—2025. Median days cash on hand increased to 215.1 days in fiscal 2024 from 211.3 days in fiscal 2023.
- L.E.K. Consulting. 2025 U.S. Health System Executive Survey, Part 2: The Financial Divide Widens. Approximately half of respondents characterized their systems as financially constrained and half as financially solid or strong; more than half reported fewer than 180 days cash on hand.
- Snapshot findings were independently reported and reviewed with the provider, revenue-cycle firm, and patient-financing partner.
The Series